Amneal Pharmaceuticals, Inc. Stock price

Equities

AMRX

US03168L1052

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
6.06 USD -0.98% Intraday chart for Amneal Pharmaceuticals, Inc. -3.66% -0.16%
Sales 2024 * 2.6B Sales 2025 * 2.73B Capitalization 1.87B
Net income 2024 * 14M Net income 2025 * 22M EV / Sales 2024 * 1.6 x
Net Debt 2024 * 2.29B Net Debt 2025 * 2.07B EV / Sales 2025 * 1.45 x
P/E ratio 2024 *
121 x
P/E ratio 2025 *
67.3 x
Employees 7,850
Yield 2024 *
-
Yield 2025 *
-
Free-Float 28.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.98%
1 week-3.66%
Current month+9.78%
1 month+9.78%
3 months-0.98%
6 months+39.95%
Current year-0.16%
More quotes
1 week
5.71
Extreme 5.71
6.21
1 month
5.01
Extreme 5.01
6.46
Current year
5.01
Extreme 5.01
6.46
1 year
1.31
Extreme 1.31
6.46
3 years
1.24
Extreme 1.24
6.91
5 years
1.24
Extreme 1.24
14.65
10 years
1.24
Extreme 1.24
24.48
More quotes
Managers TitleAgeSince
Founder 57 01-12-31
Founder 53 01-12-31
Director of Finance/CFO 57 Nov. 06
Members of the board TitleAgeSince
Director/Board Member 66 Nov. 06
Director/Board Member 69 Nov. 06
Chairman 71 Nov. 06
More insiders
Date Price Change Volume
24-03-28 6.06 -0.98% 2,883,519
24-03-27 6.12 +4.62% 1,913,485
24-03-26 5.85 -1.02% 1,895,661
24-03-25 5.91 -2.64% 889,275
24-03-22 6.07 -3.50% 2,228,526

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
6.06 USD
Average target price
7.312 USD
Spread / Average Target
+20.67%
Consensus
  1. Stock
  2. Equities
  3. Stock Amneal Pharmaceuticals, Inc. - Nasdaq